Adults 30 to 65, any sex, with Cardiovascular Diseases or Cardiovascular Abnormalities. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change From Baseline of Total Cholesterol After 90 DaysPrimary· Baseline and 90 days
Total cholesterol is the total amount of cholesterol in the blood. Change = Day 90 score - baseline score.
Group
Value
95% CI
Cardioflex Group
-0.57
± 1.06
Placebo Group
-1.09
± 1.05
Heart Rate VariabilitySecondary· Baseline and day 90
Heart rate variability is a measure of the variation in time between each heartbeat. Change = day 90 score - baseline score
Group
Value
95% CI
Cardioflex
3.49
± 10.86
Placebo
-6.27
± 10.55
Sponsor's own description
Cardiovascular diseases (CVD), primarily heart disease and stroke, are the leading causes of death and prescription drug use in Canada. Research on certain dietary supplements looks promising as a way to help reduce CVD risk factors. Studies show that supplementation of certain nutrients such as antioxidants, amino acids, electrolytes, vitamins and minerals may effectively reduce cardiovascular risk factors. The dietary supplement CardioFlex Q10, which is high in the aforementioned components, was developed to help regulate the body's production of cholesterol, strengthen the arteries and heart, and reverse oxidation.
The overall objective of this study is to determine if 90 days of supplementing with CardioFlex Q10 can reduce CVD risk factors in adults, independent of other dietary or physical activity changes.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Other recruiting trials for Cardiovascular Diseases
Currently open trials in the same condition.
NCT07442578 — Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial
· NA
· active not recruiting
NCT07426263 — Effectiveness of a Therapeutic Education Program on Female Sexuality in Women Attending Cardiac Rehabilitation.
· NA
· active not recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO
· NA
· recruiting
NCT07324278 — Hybrid Stroke Rehab With Mirror Priming
· NA
· recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under
· NA
· recruiting
Other University of Manitoba trials
Trials by the same sponsor.
NCT07528417 — Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)
· Phase 2
· not yet recruiting
NCT07366515 — Feasibility of a Multimodal Virtual Reality Intervention to Reduce Preoperative Anxiety in Cancer Surgery Patients
· NA
· not yet recruiting
NCT07354386 — Effects of Dried Whole Fruits on Metabolism in Diabetes
· NA
· enrolling by invitation
NCT07361315 — Development and Online Evaluation of an Online Course for Parasomnias
· NA
· recruiting
NCT07023744 — CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Manitoba
Last refreshed: 29 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03826914.